[go: up one dir, main page]

SA521430813B1 - لقاح وحدات فرعية لعلاج عدوى الجهاز التنفسي أو الوقاية منها - Google Patents

لقاح وحدات فرعية لعلاج عدوى الجهاز التنفسي أو الوقاية منها

Info

Publication number
SA521430813B1
SA521430813B1 SA521430813A SA521430813A SA521430813B1 SA 521430813 B1 SA521430813 B1 SA 521430813B1 SA 521430813 A SA521430813 A SA 521430813A SA 521430813 A SA521430813 A SA 521430813A SA 521430813 B1 SA521430813 B1 SA 521430813B1
Authority
SA
Saudi Arabia
Prior art keywords
respiratory tract
prevention
treatment
tract infection
subunit vaccine
Prior art date
Application number
SA521430813A
Other languages
English (en)
Inventor
مينكى أندرياس
لوندبيرج اوربن
بيروجى فابيان
شوامبورن كلاوس
شولر وولفغانغ
Original Assignee
فالنيفا سى
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by فالنيفا سى filed Critical فالنيفا سى
Publication of SA521430813B1 publication Critical patent/SA521430813B1/ar

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08—RNA viruses
    • C07K14/115—Paramyxoviridae, e.g. parainfluenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18311—Metapneumovirus, e.g. avian pneumovirus
    • C12N2760/18322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18311—Metapneumovirus, e.g. avian pneumovirus
    • C12N2760/18334—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

يتعلق الاختراع الحالي ببروتينات F للفيروس التالي لالتهاب الرئة البشري المُعدَّل Human metapneumovirus (hMPV)، المستقرة في شكل الدمج المسبق. كما يتعلق الاختراع بتركيبات مولدة للمناعة (لقاحات) تشتمل على تلك البروتينات لعلاج الخاضعين للعلاج من البشر من عدوى الجهاز التنفسي و/أو الوقاية منها. [الشكل 3]
SA521430813A 2019-05-20 2021-11-10 لقاح وحدات فرعية لعلاج عدوى الجهاز التنفسي أو الوقاية منها SA521430813B1 (ar)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP19175413 2019-05-20
PCT/EP2020/063973 WO2020234300A1 (en) 2019-05-20 2020-05-19 A subunit vaccine for treatment or prevention of a respiratory tract infection

Publications (1)

Publication Number Publication Date
SA521430813B1 true SA521430813B1 (ar) 2024-04-27

Family

ID=66685352

Family Applications (1)

Application Number Title Priority Date Filing Date
SA521430813A SA521430813B1 (ar) 2019-05-20 2021-11-10 لقاح وحدات فرعية لعلاج عدوى الجهاز التنفسي أو الوقاية منها

Country Status (21)

Country Link
US (3) US12162907B2 (ar)
EP (1) EP3972639A1 (ar)
JP (1) JP2022533318A (ar)
KR (1) KR20220010478A (ar)
CN (1) CN114127101A (ar)
AU (1) AU2020277661A1 (ar)
BR (1) BR112021021637A2 (ar)
CA (1) CA3138064A1 (ar)
CL (1) CL2021002819A1 (ar)
CO (1) CO2021014694A2 (ar)
EC (1) ECSP21079178A (ar)
GB (1) GB2598494B (ar)
IL (1) IL287099A (ar)
MX (1) MX2021013111A (ar)
MY (1) MY208001A (ar)
PE (1) PE20220400A1 (ar)
PH (1) PH12021552736A1 (ar)
SA (1) SA521430813B1 (ar)
SG (1) SG11202110646PA (ar)
WO (1) WO2020234300A1 (ar)
ZA (1) ZA202106883B (ar)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8986704B2 (en) 2012-07-06 2015-03-24 Valneva Austria Gmbh Mutant fragments of OspA and methods and uses relating thereto
CA3059817A1 (en) 2017-04-13 2018-10-18 Valneva Austria Gmbh Multivalent ospa polypeptides and methods and uses relating thereto
GB2598494B (en) 2019-05-20 2024-07-24 Valneva Se A subunit vaccine for treatment or prevention of a respiratory tract infection
EP4146253A1 (en) 2020-04-09 2023-03-15 Valneva Austria GmbH Improvements in vaccine formulations for medical use
CN116615235A (zh) 2020-10-09 2023-08-18 得克萨斯州大学系统董事会 融合前稳定的hmpv f蛋白
AU2021380755A1 (en) 2020-11-13 2023-06-22 Icosavax, Inc. Protein-based nanoparticle vaccine for metapneumovirus
CN117279659A (zh) 2021-04-09 2023-12-22 瓦尔尼瓦公司 人偏肺病毒疫苗
US20240335523A1 (en) * 2021-08-05 2024-10-10 The Regents Of The University Of California Glycoengineered Foldon Domains and Related Compositions and Methods
EP4448802A1 (en) * 2021-12-16 2024-10-23 Janssen Vaccines & Prevention B.V. Stabilized pre-fusion hmpv fusion proteins
TW202436325A (zh) 2023-01-18 2024-09-16 美商輝瑞大藥廠 針對呼吸道疾病之疫苗
KR20250144435A (ko) * 2023-02-06 2025-10-10 사이안백 엘엘씨 변형된 piv5 백신 벡터: 제조 및 사용 방법
WO2025126071A1 (en) 2023-12-14 2025-06-19 Pfizer Inc. Rna molecules
WO2025201243A1 (zh) * 2024-03-25 2025-10-02 中国医学科学院医学生物学研究所 重组呼吸道合胞病毒融合前f蛋白突变体和其用途
CN119176858A (zh) * 2024-11-22 2024-12-24 北京华诺泰生物医药科技有限公司 一种重组人偏肺病毒融合前f蛋白纯化方法

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5547871A (en) 1993-01-25 1996-08-20 American Cyanamid Company Heterologous signal sequences for secretion of insect controlling proteins
JP3468773B2 (ja) 1994-07-15 2003-11-17 ザ ユニバーシティ オブ アイオワ リサーチ ファウンデーション 免疫調節オリゴヌクレオチド
AT408721B (de) 1999-10-01 2002-02-25 Cistem Biotechnologies Gmbh Pharmazeutische zusammensetzung enthaltend ein antigen
AT409085B (de) 2000-01-28 2002-05-27 Cistem Biotechnologies Gmbh Pharmazeutische zusammensetzung zur immunmodulation und herstellung von vakzinen
DE60100814T2 (de) 2000-06-08 2004-07-01 Intercell Biomedizinische Forschungs- Und Entwicklungs Gmbh Immunstimulierende oligodeoxynukleotide
AT410173B (de) 2000-06-08 2003-02-25 Cistem Biotechnologies Gmbh Antigene zusammensetzung
WO2002013857A2 (en) 2000-08-17 2002-02-21 Intercell Biomedizinische Forschungs- Und Entwicklungs Ag A vaccine which comprises at least one antigen and a cathelididin derived antimicrobial peptide or a derivative thereof
AT410635B (de) 2000-10-18 2003-06-25 Cistem Biotechnologies Gmbh Vakzin-zusammensetzung
US8715922B2 (en) * 2001-01-19 2014-05-06 ViroNovative Virus causing respiratory tract illness in susceptible mammals
CN1526016A (zh) 2001-05-21 2004-09-01 �����ɷ� 稳定核酸的方法
EP1450821A1 (en) 2001-12-07 2004-09-01 Intercell AG Immunostimulatory oligodeoxynucleotides
DE10221836A1 (de) * 2002-05-16 2003-12-04 Lohmann Animal Health Gmbh Attenuierung von Metapneumovirus
JP4676426B2 (ja) 2003-03-24 2011-04-27 インターツェル・アクチェンゲゼルシャフト 改良型ワクチン
EP2494987A1 (en) * 2003-04-25 2012-09-05 MedImmune Vaccines, Inc. Metapneumovirus strains and their use in vaccine formulations and as vectors for expression of antigenic sequences and methods for propagating virus
MX2012000036A (es) 2009-06-24 2012-02-28 Glaxosmithkline Biolog Sa Vacuna.
WO2011050168A2 (en) 2009-10-21 2011-04-28 The United States Of America, As Represented By The Secretary, Department Of Health And Human Servic Rsv immunogens, antibodies and compositions thereof
CN102145167A (zh) * 2010-02-05 2011-08-10 重庆医科大学附属儿童医院 重组人类偏肺病毒疫苗
NO2575876T3 (ar) 2010-05-26 2018-05-05
ES2987623T3 (es) 2011-12-06 2024-11-15 Valneva Austria Gmbh Compuestos de aluminio para su uso en agentes terapéuticos y vacunas
EP3010931B1 (en) * 2013-06-17 2018-06-13 Janssen Vaccines & Prevention B.V. Stabilized soluble pre-fusion rsv f polypeptides
CL2013002829A1 (es) 2013-10-01 2014-04-04 Univ Pontificia Catolica Chile Formulacion inmunogenica que contiene bcg vivas recombinantes que expresan antigenos de metapneumovirus (hmpv) en una suspension que se prepara a partir de un liofilizado sin la necesidad de adjuvante; su uso farmaceutico; vacuna contra hmpv.
WO2016103238A1 (en) 2014-12-24 2016-06-30 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Recombinant metapneumovirus f proteins and their use
CA2996762A1 (en) * 2015-08-31 2017-03-09 Technovax, Inc. Human respiratory syncytial virus (hrsv) virus-like particles (vlps) based vaccine
EP3718565B1 (en) 2015-10-22 2022-04-27 ModernaTX, Inc. Respiratory virus vaccines
US10961283B2 (en) 2016-06-27 2021-03-30 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Self-assembling insect ferritin nanoparticles for display of co-assembled trimeric antigens
WO2019092002A1 (en) * 2017-11-07 2019-05-16 Valneva Se Pharmaceutical compositions for treatment or prevention of viral infections
GB2598494B (en) 2019-05-20 2024-07-24 Valneva Se A subunit vaccine for treatment or prevention of a respiratory tract infection
CN117279659A (zh) 2021-04-09 2023-12-22 瓦尔尼瓦公司 人偏肺病毒疫苗

Also Published As

Publication number Publication date
MX2021013111A (es) 2021-11-17
US20240067681A1 (en) 2024-02-29
ECSP21079178A (es) 2021-11-30
CN114127101A (zh) 2022-03-01
US20250171501A1 (en) 2025-05-29
JP2022533318A (ja) 2022-07-22
ZA202106883B (en) 2022-07-27
MY208001A (en) 2025-04-03
IL287099A (en) 2021-12-01
EP3972639A1 (en) 2022-03-30
PH12021552736A1 (en) 2022-07-11
SG11202110646PA (en) 2021-10-28
BR112021021637A2 (pt) 2021-12-21
PE20220400A1 (es) 2022-03-22
CO2021014694A2 (es) 2022-01-17
CL2021002819A1 (es) 2022-07-08
US12162909B2 (en) 2024-12-10
AU2020277661A1 (en) 2021-10-21
GB202114836D0 (en) 2021-12-01
CA3138064A1 (en) 2020-11-26
KR20220010478A (ko) 2022-01-25
US12162907B2 (en) 2024-12-10
WO2020234300A1 (en) 2020-11-26
US20220185847A1 (en) 2022-06-16
GB2598494B (en) 2024-07-24
GB2598494A (en) 2022-03-02

Similar Documents

Publication Publication Date Title
SA521430813B1 (ar) لقاح وحدات فرعية لعلاج عدوى الجهاز التنفسي أو الوقاية منها
CR20210306A (es) Proteínas f de prefusión del vrs estabilizadas
MX392525B (es) Composiciones inmunogenicas para su uso en vacunas neumococicas
MX2020010941A (es) Moleculas y composiciones novedosas de arn de vsr para vacunacion.
EA201070794A1 (ru) Рекомбинантные антигены rsv
MX2023010370A (es) Vacuna del metapneumovirus humano.
MX393855B (es) Terapia de combinación que comprende un inhibidor de raf y trametinib
CY1117673T1 (el) Ανασυνδυασμενα αντιγονα rsv
MX395525B (es) Composiciones inmunogenicas para usar en vacunas neumococicas.
MX2023000024A (es) Combinación vacunal contra la infección por el virus respiratorio sincicial.
MX337932B (es) Proteinas f del vrs modificadas y metodos de uso de las mismas.
PH12021550479A1 (en) Dengue vaccine unit dose and administration thereof
PH12018502332A1 (en) Stabilized pre-fusion rsv f proteins
WO2017214596A8 (en) Compositions and methods for preventing and treating zika virus infection
MX2021013947A (es) Tratamiento profilactico de la infeccion por virus sincitial respiratorio con una vacuna basada en adenovirus.
PH12013501373B1 (en) Bovine viral diarrhea virus type 1b vaccine compositions and methods
MX2020008454A (es) Composicion inmunogenica que comprende antigenos estafilococicos.
WO2022173714A3 (en) Antibodies that bind metapneumovirus, antigenic metapneumovirus proteins, and uses thereof
MY170991A (en) Dosing regimens of celgosivir for the treatment of dengue
MX2021001228A (es) Composicion para uso en la prevencion y/o tratamiento de la mucosa genitourinaria.
ATE454896T1 (de) Heilkräuterzusammensetzung zur behandlung von aids
MX2023005221A (es) Composiciones inmunogenicas para uso en vacunas neumococicas.
MX2022008036A (es) Nuevo uso de formulacion inmunogenica bcg que expresa una proteina de virus respiratorio sincicial contra hmpv.
SA520411067B1 (ar) تركيبات صلبة فموية من بيتا هستين ممتدة الإطلاق غير نابضة
MX2021015494A (es) Profarmacos de quinazolina para el tratamiento de infecciones viricas y otras enfermedades.